New York, June 12, 2026, 11:50 (EDT).
- Pfizer stock edged up Friday following its 2.23% gain on Thursday, beating the broader health-care sector.
- RBC Capital moved Pfizer up to Sector Perform and stuck with its $25 price target. The stance is more neutral than positive.
- Pfizer’s oncology readouts set for 2026 are the next key catalysts. Drug-pricing pressure in Europe is still a big risk.
Pfizer Inc. shares added 0.36% to trade around $26.27 Friday, putting its market cap at roughly $150.5 billion. The stock had climbed 2.23% Thursday, closing at $26.17, on higher-than-average volume and outperforming most major health-care names, MarketWatch said. Broader markets were higher Friday, with the SPDR S&P 500 ETF Trust up, but the Health Care Select Sector SPDR ETF was down a bit, showing Pfizer trading better than the sector in late-morning deals.
Pfizer shares got a jolt after a Wall Street analyst softened his stance. RBC Capital’s Trung Huynh lifted his rating to Sector Perform from Underperform but left the $25 price target unchanged, saying the “risk reward is now more balanced.” Sector Perform is a neutral call. The firm noted Pfizer’s drop from 2026 highs had moved the shares closer to RBC’s 9-times one-year forward P/E target. The forward P/E ratio measures the stock price against expected earnings. StreetInsider.com
That matters because stocks tend to go up when investors see a better outlook for earnings, dividends, or big drug launches, and they usually drop when profit forecasts, patent terms, or policy look worse. For Pfizer, bulls point to the roughly 6.6% dividend yield as current support for the shares while the market waits for key cancer and obesity-drug updates. Bears say a cheap valuation can stick around if trial results miss, pricing headwinds get worse, or Pfizer’s COVID sales keep falling.
Policy risk moved back into view this week after Reuters said Wednesday that Pfizer CEO Albert Bourla told German Chancellor Friedrich Merz the company is looking at the “timing, scope and future prioritization” of some projects in Germany. The review is tied to potential drug price legislation. Pricing pressure hits pharma stocks since lower reimbursed drug prices can take down future revenue, and the extra uncertainty makes investors cautious about valuations. Reuters
Next up for Pfizer is its 2026 clinical data schedule, widely seen as a key set of catalysts, especially around oncology. The company’s own list singles out data for mevrometostat in first- or second-line metastatic castration-resistant prostate cancer, along with sigvotatug vedotin in second-line-plus non-squamous metastatic non-small cell lung cancer. RBC flagged sigvotatug vedotin in mid-2026 and mevrometostat in the second half of 2026 as important for investor sentiment. When a drugmaker puts out a clinical readout—the results of a trial—the stock can move hard if the market shifts its view on future sales.
Pfizer’s financials remain uneven. First-quarter revenue came in at $14.45 billion, a 5% gain from last year. The drugmaker kept its 2026 revenue outlook in a $59.5 billion to $62.5 billion range and left its adjusted diluted EPS target at $2.80 to $3.00. Investors often look at adjusted EPS, which strips out certain items, to compare profit. Revenue from new and acquired products jumped 22% operationally. Comirnaty and Paxlovid sales kept sliding.
Pfizer is trading near fair value at current levels. Analysts tracked by MarketBeat rate the stock Hold, with an average 12-month target at $28.82—about 10% above where shares stand now. RBC’s new neutral target is $25, below the current price. That may entice yield-focused investors willing to take on pipeline and policy risk, but the stock is a tougher sell for those after quicker gains unless upcoming oncology results or company guidance point more clearly to a recovery in post-COVID profits.
